New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control
Not yet recruiting
This study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC